The chelating agent, desferrioxamine (DFO), has been used to facilitate the removal of iron during dialysis and more recently has been utilized in the treatment of patients with Al-related bone disease and encephalopathy. The DFO-Al complex, or aluminoxamine, with a molecular weight of 584, might be expected to traverse the dialysis membranes, and the administration of DFO should enhance the removal of Al by dialysis. Limited information is available regarding the effect of DFO on the kinetics of Al during dialysis. Therefore, we studied dialyzer clearances of Al both before and after the administration of DFO in hemodialysis patients with Al-related disease. The removal of Al by dialysis is minimal, but it can be enhanced by DFO. The effect of DFO is due to an increase in the ultrafilterable fraction of plasma Al and to an increase in the total plasma Al by mobilization of tissue Al stores. Thus, desferrioxamine is effective in enhancing the removal of Al by dialysis in patients with Al-related osteodystrosphy.
|Published - 1986
ASJC Scopus subject areas